Marie-Aude Khuong-Josses
Biographic Data
| ID | 7731316 |
|---|---|
| NAME | Marie-Aude Khuong-Josses |
| GIVEN NAMES | Marie-Aude |
| FAMILY NAME | Khuong-Josses |
| SIGNATURE | KHUONG-JOSSES M |
| AFFILIATIONS | Centre Hospitalier Saint-Denis |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons
We evaluated awareness of treatment as prevention (TasP) among adults people living with HIV (PLHIV) in five infectious disease departments in Paris, then how they perceived its impact on their sexual well-being. This cross-sectional multicenter survey was conducted in 2014 during scheduled clinical appointments using a self-administered questionnaire. We analyzed 520 questionnaires (42% women, 54% men of whom 57% were MSM [men who have sex with …
Patient-Reported Outcomes in Atlas and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled ana…
No prominent works on this page.
Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons
We evaluated awareness of treatment as prevention (TasP) among adults people living with HIV (PLHIV) in five infectious disease departments in Paris, then how they perceived its impact on their sexual well-being. This cross-sectional multicenter survey was conducted in 2014 during scheduled clinical appointments using a self-administered questionnaire. We analyzed 520 questionnaires (42% women, 54% men of whom 57% were MSM [men who have sex with …
Patient-Reported Outcomes in Atlas and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled ana…
Antiretroviral therapy (2 works) · Family medicine (2 works) · HIV/AIDS Research and Interventions (2 works) · Medicine (2 works) · Adolescent Sexual and Reproductive Health (1 works) · Adverse effect (1 works) · Clinical Psychology (1 works) · Cross-sectional study (1 works) · Demography (1 works) · Gerontology (1 works)